Filters

Clear all

Expert Opinion

Plain Language Summary

Expert Review

Text Availability

Abstract

Full text

Free full text

Publication Types

Journal Article

Review

Research Support, Non-U.S. Gov't

Research Support, N.I.H., Extramural

Clinical Trial

Systematic Review

Research Support, U.S. Gov't, Non-P.H.S.

Clinical Trial, Phase II

Clinical Trial, Phase I

Observational Study

Randomized Controlled Trial

Multicenter Study

Clinical Trial, Phase III

Comparative Study

Meta-Analysis

Research Support, U.S. Gov't, P.H.S.

Research Support, N.I.H., Intramural

Network Meta-Analysis

Clinical Trial Protocol

Controlled Clinical Trial

Editorial

Publication Year

From

Quick links

Individual year

2026

2025

2024

2022

2021

2020

2019

2018

2017

2016

2015

2014

2013

2009

2008

2006

2005

2004

2003

2002

2000

Sort by:

selected

Print page

Email selected articles

Favourite selected articles

Create a NED Search Alert for this search

Save this search

Advanced Search

Run an advanced search

Results for
""Glutamate Carboxypeptidase II""[mesh_terms]

76 Results

Searching titles within these results

PSMA-Targeted Positron Emission Tomography Imaging in Solid Tumors Other Than Prostate Carcinoma: An Update.

Christophe Van de Wiele, Justine Maes, Shaobo Li, Mike Sathekge, Nozipho Nyakale, Alex Maes

Seminars in nuclear medicine 2025;55(5):672-679

Full Text

Abstract

The prostate-specific membrane antigen: lessons and current clinical implications from 20 years of research.

Denise S O'Keefe, Dean J Bacich, Benjamin T Ristau

Urologic oncology 2014;32(3):272-9

Free Full Text

Abstract

Targeting prostate-specific membrane antigen for personalized therapies in prostate cancer: morphologic and molecular backgrounds and future promises.

R Montironi, S Cascinu, L Cheng, A Lopez-Beltran, R Mazzucchelli, M Scarpelli, M Santoni

Journal of biological regulators and homeostatic agents 2015;28(4):555-63

Full Text

Abstract

Prostate-specific Membrane Antigen-PET/CT in Nonprostatic Malignancies: Potential Applications in Theranostics.

Priyanka Verma, Sandip Basu

Clinical nuclear medicine 2026;51(6):e410-e421

Full Text

Abstract

A Perspective on the Evolving Story of PSMA Biology, PSMA-Based Imaging, and Endoradiotherapeutic Strategies.

Warren D W Heston, Steve S Huang, Dean J Bacich, Denise S O'Keefe

Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2019;59(7):1007-1013

Free Full Text

Abstract

PSMA PET/CT in the diagnosis of prostate cancer: why and when?

Marco Roscigno, Ludovica Pepe, Daniele Cignoli, Pietro Pepe

Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica 2025;97(2):13746

Free Full Text

Abstract

Tailored Reaction Conditions and Automated Radiolabeling of [¹⁷⁷Lu]Lu-PSMA-ALB-56 in a ⁶⁸Ga Setting: The Critical Impact of Antioxidant Concentrations.

Johanne Vanney, Léa Rubira, Jade Torchio, Cyril Fersing

International journal of molecular sciences 2025;26(19):

Full Text

Abstract

Kinetic Properties of Glutamate Carboxypeptidase II Partially Purified from Leukodystrophy Patient's Serum.

Wasan Nazhan, Aws Z Abdulmajeed

ACS chemical neuroscience 2024;15(18):3384-3390

Full Text

Abstract

F-Labeled, PSMA-Targeted Radiotracers: Leveraging the Advantages of Radiofluorination for Prostate Cancer Molecular Imaging.

Rudolf A Werner, Thorsten Derlin, Constantin Lapa, Sara Sheikbahaei, Takahiro Higuchi, Frederik L Giesel, Spencer Behr, Alexander Drzezga, Hiroyuki Kimura, Andreas K Buck, Frank M Bengel, Martin G Pomper, Michael A Gorin, Steven P Rowe

Theranostics 2021;10(1):1-16

Free Full Text

Abstract

Prostate-specific Membrane Antigen PET: Clinical Utility in Prostate Cancer, Normal Patterns, Pearls, and Pitfalls.

Michael S Hofman, Rodney J Hicks, Tobias Maurer, Matthias Eiber

Radiographics : a review publication of the Radiological Society of North America, Inc 2018;38(1):200-217

Full Text

Abstract

Prostate Cancer Imaging with Novel PET Tracers.

Liza Lindenberg, William Dahut, Peter Choyke

Current urology reports 2016;17(3):18

Free Full Text

Abstract

Safety, Biodistribution, and Radiation Dosimetry of F-rhPSMA-7.3 in Healthy Adult Volunteers.

Simona Malaspina, Kari Kalliokoski, Tuula Tolvanen, Salla Lahdenpohja, Ernst J Postema, Matthew P Miller, Mika Scheinin, Anna Kuisma

Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2021;62(5):679-684

Free Full Text

Abstract

Imaging Efficacy of [F]CTT1057 PET/CT in Patients with Biochemically Recurrent Prostate Cancer: Results from GuidePath-A Phase 3, Prospective Multicenter Study.

Jun Tang, Christelle Seigne, Medge Coulanges, Pierre Benoit Bonnefoy, Ismini Charis Mainta, Marc Simo Perdigo, Joan Duch, Pilar Paredes, Javier Jesus Robles Barba, Andrei Iagaru, Spencer Behr, Stefano Fanti, Rahul Aggarwal, Ana M Catafau, Tobias Maurer, Jochen Walz, Celine Wilke

Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2025;66(8):1210-1216

Free Full Text

Abstract

Liver Background Uptake of Prostate-specific Membrane Antigen-targeted PET Radiotracers: A Systematic Review and Meta-Analysis.

Gary A Ulaner, Ashwin S Parihar, Jeremie Calais, Siobhan Sutcliffe, Jan W Schoones

Radiology. Imaging cancer 2026;8(4):e250732

Full Text

Abstract

Imaging Efficacy of [F]CTT1057 PET for the Detection of PSMA-Positive Tumors Using Histopathology as Standard of Truth: Results from the GuideView Phase 2/3 Prospective Multicenter Study.

Celine Wilke, Zhongying Xu, Christelle Seigne, Nicolas Doumerc, Thomas Penhoat, Nicolo Buffi, Jose F Suarez, Medge Coulanges, Pilar Paredes, Andrei Iagaru, Spencer Behr, Stefano Fanti, Rahul Aggarwal, Ana M Catafau, Tobias Maurer, Francesco Ceci, Jochen Walz

Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2025;66(8):1232-1238

Free Full Text

Abstract

Results: 1 – 15 / 76

Filters

Expert Opinion

Text Availability

Publication Types

Publication Year

Results for ""Glutamate Carboxypeptidase II""[mesh_terms]

PSMA-Targeted Positron Emission Tomography Imaging in Solid Tumors Other Than Prostate Carcinoma: An Update.

The prostate-specific membrane antigen: lessons and current clinical implications from 20 years of research.

Targeting prostate-specific membrane antigen for personalized therapies in prostate cancer: morphologic and molecular backgrounds and future promises.

Prostate-specific Membrane Antigen-PET/CT in Nonprostatic Malignancies: Potential Applications in Theranostics.

A Perspective on the Evolving Story of PSMA Biology, PSMA-Based Imaging, and Endoradiotherapeutic Strategies.

PSMA PET/CT in the diagnosis of prostate cancer: why and when?

Tailored Reaction Conditions and Automated Radiolabeling of [177Lu]Lu-PSMA-ALB-56 in a 68Ga Setting: The Critical Impact of Antioxidant Concentrations.

Kinetic Properties of Glutamate Carboxypeptidase II Partially Purified from Leukodystrophy Patient's Serum.

F-Labeled, PSMA-Targeted Radiotracers: Leveraging the Advantages of Radiofluorination for Prostate Cancer Molecular Imaging.

Prostate-specific Membrane Antigen PET: Clinical Utility in Prostate Cancer, Normal Patterns, Pearls, and Pitfalls.

Prostate Cancer Imaging with Novel PET Tracers.

Safety, Biodistribution, and Radiation Dosimetry of F-rhPSMA-7.3 in Healthy Adult Volunteers.

Imaging Efficacy of [F]CTT1057 PET/CT in Patients with Biochemically Recurrent Prostate Cancer: Results from GuidePath-A Phase 3, Prospective Multicenter Study.

Liver Background Uptake of Prostate-specific Membrane Antigen-targeted PET Radiotracers: A Systematic Review and Meta-Analysis.

Imaging Efficacy of [F]CTT1057 PET for the Detection of PSMA-Positive Tumors Using Histopathology as Standard of Truth: Results from the GuideView Phase 2/3 Prospective Multicenter Study.

Results for
""Glutamate Carboxypeptidase II""[mesh_terms]

Tailored Reaction Conditions and Automated Radiolabeling of [¹⁷⁷Lu]Lu-PSMA-ALB-56 in a ⁶⁸Ga Setting: The Critical Impact of Antioxidant Concentrations.